<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
      <JournalTitle>Frontiers in Medical Case Reports</JournalTitle>
      <Volume-Issue>Volume 1; Issue 2</Volume-Issue>
      <Season>(Mar-Apr, 2020)</Season>
      <ArticleType>Medical Case Reports</ArticleType>
      <ArticleTitle>Burkholderia Cepacia Sepsis: A Neonatal Case</ArticleTitle>
          <FirstName>F Bennaoui</FirstName>
          <FirstName>N EL Idrissi</FirstName>
      <Abstract>Burkholderia Cepacia is an aerobic, glucose non-fermenting, motile and multidrug resistant gram negative bacteria; which is not considered from the normal human flora. It is a rare cause of sepsis in newborns and its transmission involves human contact with heavily contaminated medical devices and disinfectants.&#13;
We are describing a rare case of sepsis by Burkholderia Cepacia in a pre-term infant, diagnosed in Neonatal Intensive Care unit, University hospital; Marrakesh.&#13;
He was a male newborn, he was a pre-term with intrauterine growth retarded, he was admitted for sepsis. The diagnosis was made by blood culture. The treatment was a bi-antibiotic treatment: imipenem and aminoglycoside. The outcome was fatal after 9 days.&#13;
Burkholderia Cepacia is a nosocomial pathogen of humans in both immunocompromised and hospitalized patients . It causes infections that are proving difficult to treat because of both high intrinsic (aminoglycosides and colistin) and acquired resistance (__ampersandsignbeta;-lactams). We conclude that the drugs are already limited in this bacteria. Progress remains to be made in antibiotic therapy, as often molecules are active in vitro and especially in vivo.</Abstract>
      <Keywords>Bacteremia,Burkholderia cepacia complex,Neonatal,Sepsis</Keywords>
        <Abstract>https://jmedicalcasereports.org/ubijournal-v1copy/journals/abstract.php?article_id=7293&amp;title=Burkholderia Cepacia Sepsis: A Neonatal Case</Abstract>
        <References>Akinboyo IC, Sick-Samuels AC, Singeltary E, Fackler J, Ascenzi J, Carroll KC, Maldonado Y, Brooks RB, Benowitz I, Wilson LE, LiPuma JJ, Milstone AM. Multistate Outbreak of an Emerging Burkholderia cepacia Complex Strain Associated with Contaminated Oral Liquid Docusate Sodium. Infect Control Hosp Epidemiol 2018; 39: 237-239.&#13;
Anderson DJ, Kuhns JS, Vasil ML, Gerding DN, Janoff EN. DNA fingerprinting by pulsed field gel electrophoresis and ribotyping to distinguish Pseudomonas cepacia isolates from a nosocomial outbreak. J Clin Microbiol 1991; 29: 648-649.&#13;
Gautam V, Singhal L, Ray P. Burkholderia cepacia complex: Beyond Pseudomonas and Acinetobacter. Indian J Med Microbiol 2011; 29: 4-12&#13;
Goldmann D and Klinger J. Pseudomonas cepacia: biology, mechanisms of virulence, epidemiology. J Pediatr 1986; 108: 806-812.&#13;
Mali S, Dash L, Gautam V, Shastri J, Kumar S. An outbreak of Burkholderia cepacia complex in the paediatric unit of a tertiary care hospital. Indian J Med Microbiol 2017; 35: 216-220.&#13;
Narayanaswamy VP, Giatpaiboon S, Baker SM, Wiesmann WP, LiPuma JJ, Townsend SM. Novel glycopolymer sensitizes Burkholderia cepacia complex isolates from cystic fibrosis patients to tobramycin and meropenem. PLoS One 2017; 12: e0179776.&#13;
Nivedhana S, Sulochana P, Shobana R. Spontaneous septic arthritis due to Burkholderia cepacia in a 3-month-old pre-term infant. Indian J Med Microbiol 2016; 34: 394-395.&#13;
Van Dalem A, Herpol M, Echahidi F, Peeters C, Wybo I, De Wachter E, Vandamme P, Piand;eacute;rard D. In vitro susceptibility of Burkholderia cepacia complex isolated from cystic fibrosis patients to ceftazidime-avibactam and ceftolozane-tazobactam. Antimicrob Agents Chemother 2018; pii: AAC.00590-18.</References>